Matches in SemOpenAlex for { <https://semopenalex.org/work/W2760934854> ?p ?o ?g. }
- W2760934854 endingPage "139" @default.
- W2760934854 startingPage "128" @default.
- W2760934854 abstract "Background & AimsOutcomes of liver transplantation for hepatocellular carcinoma (HCC) are determined by cancer-related and non-related events. Treatments for hepatitis C virus infection have reduced non-cancer events among patients receiving liver transplants, so reducing HCC-related death might be an actionable end point. We performed a competing-risk analysis to evaluate factors associated with survival of patients with HCC and developed a prognostic model based on features of HCC patients before liver transplantation.MethodsWe performed multivariable competing-risk regression analysis to identify factors associated with HCC-specific death of patients who underwent liver transplantation. The training set comprised 1018 patients who underwent liver transplantation for HCC from January 2000 through December 2013 at 3 tertiary centers in Italy. The validation set comprised 341 consecutive patients who underwent liver transplantation for HCC during the same period at the Liver Cancer Institute in Shanghai, China. We collected pretransplantation data on etiology of liver disease, number and size of tumors, patient level of α-fetoprotein (AFP), model for end-stage liver disease score, tumor stage, numbers and types of treatment, response to treatments, tumor grade, microvascular invasion, dates, and causes of death. Death was defined as HCC-specific when related to HCC recurrence after transplantation, disseminated extra- and/or intrahepatic tumor relapse and worsened liver function in presence of tumor spread. The cumulative incidence of death was segregated for hepatitis C virus status.ResultsIn the competing-risk regression, the sum of tumor number and size and of log10 level of AFP were significantly associated with HCC-specific death (P < .001), returning an average c-statistic of 0.780 (95% confidence interval, 0.763−0.798). Five-year cumulative incidence of non−HCC-related death was 8.6% in HCV-negative patients and 18.1% in HCV-positive patients. For patients with HCC to have a 70% chance of HCC-specific survival 5 years after transplantation, their level of AFP should be <200 ng/mL and the sum of number and size of tumors (in centimeters) should not exceed 7; if the level of AFP was 200−400 ng/mL, the sum of the number and size of tumors should be ≤5; if their level of AFP was 400−1000 ng/mL, the sum of the number and size of tumors should be ≤4. In the validation set, the model identified patients who survived 5 years after liver transplantation with 0.721 accuracy (95% confidence interval, 0.648%−0.793%). Our model, based on patients’ level of AFP and HCC number and size, outperformed the Milan; University of California, San Francisco; Shanghai-Fudan; Up-to-7 criteria (P < .001); and AFP French model (P = .044) to predict which patients will survive for 5 years after liver transplantation.ConclusionsWe developed a model based on level of AFP, tumor size, and tumor number, to determine risk of death from HCC-related factors after liver transplantation. This model might be used to select end points and refine selection criteria for liver transplantation for patients with HCC. To predict 5-year survival and risk of HCC-related death using an online calculator, please see www.hcc-olt-metroticket.org/. ClinicalTrials.gov ID NCT02898415. Outcomes of liver transplantation for hepatocellular carcinoma (HCC) are determined by cancer-related and non-related events. Treatments for hepatitis C virus infection have reduced non-cancer events among patients receiving liver transplants, so reducing HCC-related death might be an actionable end point. We performed a competing-risk analysis to evaluate factors associated with survival of patients with HCC and developed a prognostic model based on features of HCC patients before liver transplantation. We performed multivariable competing-risk regression analysis to identify factors associated with HCC-specific death of patients who underwent liver transplantation. The training set comprised 1018 patients who underwent liver transplantation for HCC from January 2000 through December 2013 at 3 tertiary centers in Italy. The validation set comprised 341 consecutive patients who underwent liver transplantation for HCC during the same period at the Liver Cancer Institute in Shanghai, China. We collected pretransplantation data on etiology of liver disease, number and size of tumors, patient level of α-fetoprotein (AFP), model for end-stage liver disease score, tumor stage, numbers and types of treatment, response to treatments, tumor grade, microvascular invasion, dates, and causes of death. Death was defined as HCC-specific when related to HCC recurrence after transplantation, disseminated extra- and/or intrahepatic tumor relapse and worsened liver function in presence of tumor spread. The cumulative incidence of death was segregated for hepatitis C virus status. In the competing-risk regression, the sum of tumor number and size and of log10 level of AFP were significantly associated with HCC-specific death (P < .001), returning an average c-statistic of 0.780 (95% confidence interval, 0.763−0.798). Five-year cumulative incidence of non−HCC-related death was 8.6% in HCV-negative patients and 18.1% in HCV-positive patients. For patients with HCC to have a 70% chance of HCC-specific survival 5 years after transplantation, their level of AFP should be <200 ng/mL and the sum of number and size of tumors (in centimeters) should not exceed 7; if the level of AFP was 200−400 ng/mL, the sum of the number and size of tumors should be ≤5; if their level of AFP was 400−1000 ng/mL, the sum of the number and size of tumors should be ≤4. In the validation set, the model identified patients who survived 5 years after liver transplantation with 0.721 accuracy (95% confidence interval, 0.648%−0.793%). Our model, based on patients’ level of AFP and HCC number and size, outperformed the Milan; University of California, San Francisco; Shanghai-Fudan; Up-to-7 criteria (P < .001); and AFP French model (P = .044) to predict which patients will survive for 5 years after liver transplantation. We developed a model based on level of AFP, tumor size, and tumor number, to determine risk of death from HCC-related factors after liver transplantation. This model might be used to select end points and refine selection criteria for liver transplantation for patients with HCC. To predict 5-year survival and risk of HCC-related death using an online calculator, please see www.hcc-olt-metroticket.org/. ClinicalTrials.gov ID NCT02898415." @default.
- W2760934854 created "2017-10-20" @default.
- W2760934854 creator A5000883758 @default.
- W2760934854 creator A5029634246 @default.
- W2760934854 creator A5032121417 @default.
- W2760934854 creator A5032258617 @default.
- W2760934854 creator A5039259452 @default.
- W2760934854 creator A5040481562 @default.
- W2760934854 creator A5047999645 @default.
- W2760934854 creator A5049022216 @default.
- W2760934854 creator A5055815413 @default.
- W2760934854 creator A5064599624 @default.
- W2760934854 creator A5070334439 @default.
- W2760934854 creator A5072516824 @default.
- W2760934854 date "2018-01-01" @default.
- W2760934854 modified "2023-10-14" @default.
- W2760934854 title "Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma" @default.
- W2760934854 cites W1483808757 @default.
- W2760934854 cites W1881850874 @default.
- W2760934854 cites W1997012350 @default.
- W2760934854 cites W2002505994 @default.
- W2760934854 cites W2008423320 @default.
- W2760934854 cites W2013320805 @default.
- W2760934854 cites W2019503533 @default.
- W2760934854 cites W2019607817 @default.
- W2760934854 cites W2021299297 @default.
- W2760934854 cites W2038981426 @default.
- W2760934854 cites W2045873713 @default.
- W2760934854 cites W2079586464 @default.
- W2760934854 cites W2102942095 @default.
- W2760934854 cites W2118698732 @default.
- W2760934854 cites W2145755811 @default.
- W2760934854 cites W2153935627 @default.
- W2760934854 cites W2154985508 @default.
- W2760934854 cites W2155069705 @default.
- W2760934854 cites W2161689638 @default.
- W2760934854 cites W2163403599 @default.
- W2760934854 cites W2165933819 @default.
- W2760934854 cites W2257705098 @default.
- W2760934854 cites W2315027248 @default.
- W2760934854 cites W2320064477 @default.
- W2760934854 cites W2395056006 @default.
- W2760934854 cites W2479602527 @default.
- W2760934854 cites W4245784696 @default.
- W2760934854 doi "https://doi.org/10.1053/j.gastro.2017.09.025" @default.
- W2760934854 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28989060" @default.
- W2760934854 hasPublicationYear "2018" @default.
- W2760934854 type Work @default.
- W2760934854 sameAs 2760934854 @default.
- W2760934854 citedByCount "367" @default.
- W2760934854 countsByYear W27609348542018 @default.
- W2760934854 countsByYear W27609348542019 @default.
- W2760934854 countsByYear W27609348542020 @default.
- W2760934854 countsByYear W27609348542021 @default.
- W2760934854 countsByYear W27609348542022 @default.
- W2760934854 countsByYear W27609348542023 @default.
- W2760934854 crossrefType "journal-article" @default.
- W2760934854 hasAuthorship W2760934854A5000883758 @default.
- W2760934854 hasAuthorship W2760934854A5029634246 @default.
- W2760934854 hasAuthorship W2760934854A5032121417 @default.
- W2760934854 hasAuthorship W2760934854A5032258617 @default.
- W2760934854 hasAuthorship W2760934854A5039259452 @default.
- W2760934854 hasAuthorship W2760934854A5040481562 @default.
- W2760934854 hasAuthorship W2760934854A5047999645 @default.
- W2760934854 hasAuthorship W2760934854A5049022216 @default.
- W2760934854 hasAuthorship W2760934854A5055815413 @default.
- W2760934854 hasAuthorship W2760934854A5064599624 @default.
- W2760934854 hasAuthorship W2760934854A5070334439 @default.
- W2760934854 hasAuthorship W2760934854A5072516824 @default.
- W2760934854 hasBestOaLocation W27609348542 @default.
- W2760934854 hasConcept C121608353 @default.
- W2760934854 hasConcept C126322002 @default.
- W2760934854 hasConcept C143998085 @default.
- W2760934854 hasConcept C2776231280 @default.
- W2760934854 hasConcept C2776455275 @default.
- W2760934854 hasConcept C2777075537 @default.
- W2760934854 hasConcept C2778019345 @default.
- W2760934854 hasConcept C2779250428 @default.
- W2760934854 hasConcept C2779609443 @default.
- W2760934854 hasConcept C2911091166 @default.
- W2760934854 hasConcept C71924100 @default.
- W2760934854 hasConcept C88879693 @default.
- W2760934854 hasConcept C90924648 @default.
- W2760934854 hasConceptScore W2760934854C121608353 @default.
- W2760934854 hasConceptScore W2760934854C126322002 @default.
- W2760934854 hasConceptScore W2760934854C143998085 @default.
- W2760934854 hasConceptScore W2760934854C2776231280 @default.
- W2760934854 hasConceptScore W2760934854C2776455275 @default.
- W2760934854 hasConceptScore W2760934854C2777075537 @default.
- W2760934854 hasConceptScore W2760934854C2778019345 @default.
- W2760934854 hasConceptScore W2760934854C2779250428 @default.
- W2760934854 hasConceptScore W2760934854C2779609443 @default.
- W2760934854 hasConceptScore W2760934854C2911091166 @default.
- W2760934854 hasConceptScore W2760934854C71924100 @default.
- W2760934854 hasConceptScore W2760934854C88879693 @default.
- W2760934854 hasConceptScore W2760934854C90924648 @default.
- W2760934854 hasIssue "1" @default.
- W2760934854 hasLocation W27609348541 @default.